Abstract 106P
Background
Polyps are considered as obligate precancerous disease. Different authors consider that percent of malignization ranges from 20% in single polyps to 95% in diffuse polyposis. Current research examines the results of the early diagnosis of colon cancer by using the biomarker CDKN2A for development of molecular-biological methods of prognostication.
Methods
Investigations were carried out in 30 patients during the period 2017-2019, the study included patients with single polyps, multiple polyps, polyposis of the colon, as well as patients without a history of neither familial nor sporadic cancer. 21 patients had polyposis, in 9 single colon polyps. The men were 19 women 11. The average age of patients was 52,4 ± 3,8 years. The levels of methylation of the gene CDKN2A were determined 18 patients. The material for the isolation of DNA was a serum obtained from venous blood and and biopsy material in amount of 50 mg. DNA extraction was held according to standards. After the conversion of DNA methyl-specific PCR was held.
Results
Among 30 patients with polyps and polyposis of the colon serum gene CDKN2A methylated DNA was detected in 18 patients. In 4 patients malignization of the polyp was determined. The volume of surgical intervention in patients with malignization was the same as cancer. It patients without malignization surgical intervention was limited with resection of the intestine without lymph dessection. In 8 patients the test result was negative. We did not perform surgical intervention to these patients they were sent to dynamic observation. Thus, the diagnostic efficacy in detection colorectal cancer in early diagnosis of by means of methylated DNA of the gene CDKN2A was - 60.1%.
Conclusions
If there is a positive test for methylation of the CDKN2A-gene, the risk of colorectal cancer is considered very high and these patients underwent surgical treatment. Application of molecular biological marker CDKN2A may be an effective method in early diagnosis of malignization of polyps. This method of diagnosis requires a more in-depth study, based on a study of a larger number of observations. Further investigations of the CDKN2a gene in ulcerative colitis, Krohn's disease, Lynch syndrome, Jeghers syndrome might be continued.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
NCC of Uzbekistan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract